Mormino Elizabeth C, Biber Sarah A, Rahman-Filipiak Annalise, Arfanakis Konstantinos, Clark Lindsay, Dage Jeffrey L, Detre John A, Dickerson Bradford C, Donohue Michael C, Kecskemeti Steven, Hohman Timothy J, Jagust William J, Keene Dirk C, Kukull Walter, Levendovszky Swati R, Rosen Howie, Thompson Paul M, Villemagne Victor L, Wolk David A, Okonkwo Ozioma C, Rabinvovici Gil D, Rivera-Mindt Monica, Foroud Tatiana, Johnson Sterling C
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Cogen Facility, Stanford, California, USA.
Alzheimers Dement. 2025 Jan;21(1):e14383. doi: 10.1002/alz.14383. Epub 2024 Nov 26.
The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address this gap. The ADRCs longitudinally follow ≈ 17,000 participants, ranging from cognitively unimpaired to dementia, arising from Alzheimer's disease (AD) and related dementias (ADRD; e.g., AD, Lewy body disorders, vascular). Motivated by the Alzheimer's Disease Neuroimaging Initiative's (ADNI) impact, the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) was formed. Leveraging existing ADRC infrastructure, CLARiTI will integrate standardized imaging and plasma collection to characterize mixed pathologies and use community-engaged research methods to ensure that ≥ 25% of the sample is from underrepresented populations (e.g., ethnoculturally minoritized, low education). The resulting ADRD profiles, within a more diverse sample, will provide key resources for ADRCs and an unprecedented, more generalizable publicly available imaging-plasma dataset. HIGHLIGHTS: In vivo detection of mixed pathologies is critical for Alzheimer's disease and related dementias research. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address gaps related to mixed pathologies. The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will enhance this national program by adding standardized imaging and plasma collection to existing ADRC infrastructure. This effort will provide key resources for ADRCs and an unprecedented publicly available imaging-plasma-neuropath dataset.
多种病理状况的存在是痴呆症最大的预测因素。该领域的一个主要差距在于对混合病理状况及其先兆进行体内检测。阿尔茨海默病研究中心（ADRCs）在解决这一差距方面具有独特的优势。ADRCs对约17000名参与者进行纵向跟踪，这些参与者涵盖认知未受损到患有痴呆症的人群，病因包括阿尔茨海默病（AD）及相关痴呆症（ADRD；例如，AD、路易体障碍、血管性痴呆）。受阿尔茨海默病神经影像学倡议（ADNI）的影响，成立了ADRD研究影像清晰度ADRC联盟（CLARiTI）。CLARiTI利用现有的ADRC基础设施，将整合标准化成像和血浆采集以表征混合病理状况，并使用社区参与研究方法确保样本中至少25%来自代表性不足的人群（例如，少数族裔文化群体、低教育水平人群）。在更多样化样本中生成的ADRD概况，将为ADRCs提供关键资源，并提供一个前所未有的、更具普遍性的公开可用成像 - 血浆数据集。要点：对混合病理状况进行体内检测对阿尔茨海默病和相关痴呆症研究至关重要。阿尔茨海默病研究中心（ADRCs）在解决与混合病理状况相关的差距方面具有独特优势。ADRD研究影像清晰度ADRC联盟（CLARiTI）将通过在现有ADRC基础设施中增加标准化成像和血浆采集来加强这一国家项目。这项工作将为ADRCs提供关键资源，并提供一个前所未有的公开可用成像 - 血浆 - 神经病理数据集。
